Aquestive Therapeutics, Inc. (AQST)
USD 2.52
(2.02%)
USD 2.52
(2.02%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 163.9 Million USD | -5.93% |
| 2022 | 174.22 Million USD | 20.89% |
| 2021 | 144.12 Million USD | 29.4% |
| 2020 | 111.38 Million USD | 31.65% |
| 2019 | 84.6 Million USD | 10.2% |
| 2018 | 76.77 Million USD | 10.29% |
| 2017 | 69.61 Million USD | 22.2% |
| 2016 | 56.96 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 165.82 Million USD | 1.17% |
| 2024 Q2 | 153.08 Million USD | -7.68% |
| 2024 Q3 | 155.37 Million USD | 1.5% |
| 2023 Q3 | 162.37 Million USD | -0.78% |
| 2023 Q4 | 163.9 Million USD | 0.94% |
| 2023 FY | 163.9 Million USD | -5.93% |
| 2023 Q1 | 170.52 Million USD | -2.13% |
| 2023 Q2 | 163.64 Million USD | -4.03% |
| 2022 Q4 | 174.22 Million USD | 9.12% |
| 2022 Q3 | 159.66 Million USD | 4.58% |
| 2022 Q2 | 152.66 Million USD | 2.0% |
| 2022 FY | 174.22 Million USD | 20.89% |
| 2022 Q1 | 149.67 Million USD | 3.85% |
| 2021 Q4 | 144.12 Million USD | 14.72% |
| 2021 Q2 | 120.64 Million USD | 6.09% |
| 2021 Q3 | 125.63 Million USD | 4.14% |
| 2021 FY | 144.12 Million USD | 29.4% |
| 2021 Q1 | 113.72 Million USD | 2.1% |
| 2020 Q1 | 85.31 Million USD | 0.85% |
| 2020 FY | 111.38 Million USD | 31.65% |
| 2020 Q4 | 111.38 Million USD | 28.11% |
| 2020 Q3 | 86.94 Million USD | 2.36% |
| 2020 Q2 | 84.93 Million USD | -0.45% |
| 2019 Q4 | 84.6 Million USD | 1.59% |
| 2019 Q3 | 83.27 Million USD | 10.94% |
| 2019 Q2 | 75.06 Million USD | 1.39% |
| 2019 Q1 | 74.03 Million USD | -3.56% |
| 2019 FY | 84.6 Million USD | 10.2% |
| 2018 Q1 | 68.9 Million USD | -1.02% |
| 2018 FY | 76.77 Million USD | 10.29% |
| 2018 Q3 | 66.56 Million USD | -15.51% |
| 2018 Q4 | 76.77 Million USD | 15.33% |
| 2018 Q2 | 78.78 Million USD | 14.35% |
| 2017 FY | 69.61 Million USD | 22.2% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | 69.61 Million USD | 0.0% |
| 2016 FY | 56.96 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 82.708% |
| Embecta Corp. | 2.03 Billion USD | 91.95% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 65.25% |
| Dynavax Technologies Corporation | 375.02 Million USD | 56.295% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 75.196% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 76.727% |
| PainReform Ltd. | 2.69 Million USD | -5990.858% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -2569.636% |
| SCYNEXIS, Inc. | 55.45 Million USD | -195.591% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -1682.233% |
| Cosmos Health Inc. | 30.25 Million USD | -441.789% |
| Journey Medical Corporation | 56.49 Million USD | -190.102% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -2569.636% |
| Safety Shot Inc | 3.89 Million USD | -4111.283% |
| Alpha Teknova, Inc. | 38.55 Million USD | -325.164% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -19.751% |
| Bright Green Corporation | 6.43 Million USD | -2445.859% |
| Procaps Group, S.A. | 462.06 Million USD | 64.528% |
| Theratechnologies Inc. | 98.63 Million USD | -66.167% |
| Harrow Health, Inc. | 241.75 Million USD | 32.201% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -1771.916% |
| Biofrontera Inc. | 23.13 Million USD | -608.35% |
| DURECT Corporation | 30.4 Million USD | -439.055% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 66.376% |
| Cronos Group Inc. | 43.73 Million USD | -274.759% |
| OptiNose, Inc. | 194.33 Million USD | 15.659% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 79.947% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -238.332% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -681.314% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 9.626% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -4245.153% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -212.104% |
| Radius Health, Inc. | 804.29 Million USD | 79.621% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -1091.661% |
| ProPhase Labs, Inc. | 42.54 Million USD | -285.26% |
| Phibro Animal Health Corporation | 725.54 Million USD | 77.409% |
| Procaps Group S.A. | 462.06 Million USD | 64.528% |
| Alvotech | 1.88 Billion USD | 91.294% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -1068.913% |
| Viatris Inc. | 27.21 Billion USD | 99.398% |
| Rockwell Medical, Inc. | 30.88 Million USD | -430.746% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -81.353% |
| SIGA Technologies, Inc. | 57.97 Million USD | -182.706% |
| Tilray Brands, Inc. | 892.11 Million USD | 81.627% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 25.43% |
| Shineco, Inc. | 47.6 Million USD | -244.326% |
| PetIQ, Inc. | 645.22 Million USD | 74.597% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -74567.9% |
| Incannex Healthcare Limited | 5.83 Million USD | -2711.407% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 83.921% |
| Alimera Sciences, Inc. | 107.35 Million USD | -52.677% |
| Silver Spike Investment Corp. | 3 Million USD | -5345.655% |
| Assertio Holdings, Inc. | 148.41 Million USD | -10.436% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -8544.938% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -668.938% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -2232.835% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -1830.445% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 5.469% |
| Hempacco Co., Inc. | 18.82 Million USD | -770.797% |
| Talphera, Inc. | 6.29 Million USD | -2505.803% |
| Alvotech | 1.88 Billion USD | 91.294% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 5.038% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 80.377% |
| Currenc Group, Inc. | 177.67 Million USD | 7.75% |
| Kamada Ltd. | 109.96 Million USD | -49.048% |
| Indivior PLC | 1.95 Billion USD | 91.6% |
| Evoke Pharma, Inc. | 9.64 Million USD | -1598.835% |
| Flora Growth Corp. | 17.22 Million USD | -851.719% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -1830.445% |
| Evolus, Inc. | 209.68 Million USD | 21.833% |
| HUTCHMED (China) Limited | 536.38 Million USD | 69.443% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 81.236% |
| Akanda Corp. | 12.66 Million USD | -1193.76% |